Evaro raises £18.3m Series A to embed NHS‑licensed prescription services into apps
This article covers Evaro, a healthtech startup that has closed a Series A funding round of £18.3m. The funding supports expansion of its NHS-licensed digital platform that embeds prescription services into consumer apps and retail sites, targeting patients needing routine care and helping to relieve pressure on GP services in the UK.
Evaro, a healthtech startup, has closed a series A funding round of £18.3 million. The NHS-licensed digital healthcare platform, which already serves more than 2 million patients, embeds prescription services into consumer apps and retail sites — aiming to create new routes to care at a time when GP waits are lengthening across the UK.
Why it matters
GP access is under strain: 20.5 million people experienced month-long waits for a GP appointment in 2024, a 60% rise over seven years. Services that can safely shift routine, low-complexity care away from in-person appointments matter for NHS capacity and patient convenience.
Evaro says it offers regulated infrastructure for asynchronous consultations, remote diagnostics, prescribing, dispensing and aftercare. The company holds CQC and GPhC licences since 2018, lists seven active regulatory approvals and has NHS integration enabling GP record access for safer prescribing. It serves more than 2 million patients today and aims to reach 10 million over the next three years. Its 4.5 Trustpilot rating is cited as a signal of patient satisfaction.
Inside the product
Evaro provides an API-first platform that partners can embed into existing customer journeys. The model supports three routes to market: consumer brands looking to add health services and new revenue streams; healthcare providers expanding digital capacity for common conditions; and employers offering health benefits.
Existing partnerships include period-tracking app Clue and sexual wellness retailer Lovehoney. Clue is a widely used menstrual health app; Lovehoney is a direct-to-consumer sexual wellness retailer. In both cases Evaro integrates prescription services directly into the user experience, which the company says can be completed in as little as two weeks. Planned product development areas mentioned by the company include women’s and men’s health, longevity medicine, diagnostics and aftercare features.
Who are the investors?
The Series A was announced with a lead investor and a group of participants. The round was led by AlbionVC, with participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC and BBI. As part of the deal, AlbionVC’s partner joins Evaro’s board.
In the announcement, Christoph Ruedig, Partner at AlbionVC, said:
We’ve seen embedded finance transform banking, Evaro is now driving the embedded health revolution. What sets Evaro apart is the depth of their regulatory stack. Evaro has spent seven years building its infrastructure properly, with deep regulatory credentials. This now allows consumer brands to enter the healthcare space safely, unlocking massive latent demand while relieving pressure on the NHS. We are thrilled to back the team as they define this new category.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
In the announcement, Dr. Thuria Wenbar, CEO and co-founder at Evaro, said:
When a third of people are waiting over a week just to see their GP, it’s time to think through alternative solutions that help people get the care they need while supporting NHS capacity. What we’ve built is infrastructure that allows our partners – brands people already trust – to deliver safe and regulated healthcare for common conditions without having to build a thing. We’re making healthcare as accessible as online banking, and this funding lets us prove that model works at scale.
In the announcement, Dr. Oskar Wenbar, Chief Medical Officer and co-founder at Evaro, said:
Patients now expect the same convenience from healthcare that they get from banking or shopping—instant, mobile, on their terms. The technology exists to deliver this for minor conditions, but our system is still stuck requiring appointments, phone calls, physical visits – with no capacity for smart aftercare. We want to solve this, and scale the infrastructure that matches how people actually want to access care in 2026.
The pair founded Evaro in 2018; both bring clinical backgrounds (emergency medicine and pharmacy research) to the product and regulatory work the company highlights.
The bigger picture
Evaro pitches itself as part of an “embedded health” trend similar to embedded finance, where non-health brands integrate regulated services into their customer experiences. If properly governed, embedding care into trusted consumer touchpoints could reduce friction for patients and divert routine demand from overstretched primary care routes.
For the UK healthtech ecosystem, the deal is another sign that investors continue to back companies promising regulatory-compliant infrastructure rather than single-condition point solutions. The commitment to regulatory approvals and NHS integration will be watched closely as a test of whether consumer brands can safely host prescription services at scale.
The outcome will influence how employers, retailers and consumer apps approach health benefits and services across the UK and Europe.
They've invested in Evaro
Get to know these healthtech investors
Click here for a full list of 7,526+ startup investors in the UK